211 related articles for article (PubMed ID: 19474471)
1. Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in Benin.
Zannou DM; Denoeud L; Lacombe K; Amoussou-Guenou D; Bashi J; Akakpo J; Gougounon A; Akondé A; Adé G; Houngbé F; Girard PM
Antivir Ther; 2009; 14(3):371-80. PubMed ID: 19474471
[TBL] [Abstract][Full Text] [Related]
2. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
[TBL] [Abstract][Full Text] [Related]
3. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.
Martinez E; Mocroft A; García-Viejo MA; Pérez-Cuevas JB; Blanco JL; Mallolas J; Bianchi L; Conget I; Blanch J; Phillips A; Gatell JM
Lancet; 2001 Feb; 357(9256):592-8. PubMed ID: 11558485
[TBL] [Abstract][Full Text] [Related]
4. Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
Guaraldi G; Zona S; Orlando G; Carli F; Stentarelli C; Luzi K; Garlassi E; Menozzi M; Bagni P; Adorni F
Clin Drug Investig; 2011 Nov; 31(11):759-67. PubMed ID: 21919542
[TBL] [Abstract][Full Text] [Related]
5. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study.
Galli M; Cozzi-Lepri A; Ridolfo AL; Gervasoni C; Ravasio L; Corsico L; Gianelli E; Vaccarezza M; Vullo V; Cargnel A; Minoli L; Coronado O; Giacometti A; Antinori A; Antonucci G; D'Arminio Monforte A; Moroni M;
Arch Intern Med; 2002 Dec 9-23; 162(22):2621-8. PubMed ID: 12456235
[TBL] [Abstract][Full Text] [Related]
6. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Aurpibul L; Puthanakit T; Lee B; Mangklabruks A; Sirisanthana T; Sirisanthana V
Antivir Ther; 2007; 12(8):1247-54. PubMed ID: 18240864
[TBL] [Abstract][Full Text] [Related]
7. Lipodystrophy induced by combination antiretroviral therapy in HIV/AIDS patients: a Belgrade cohort study.
Dragović G; Danilović D; Dimić A; Jevtović D
Vojnosanit Pregl; 2014 Aug; 71(8):746-50. PubMed ID: 25181834
[TBL] [Abstract][Full Text] [Related]
8. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy.
Barbaro G; Di Lorenzo G; Cirelli A; Grisorio B; Lucchini A; Hazra C; Barbarini G
Clin Ther; 2003 Sep; 25(9):2405-18. PubMed ID: 14604740
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort.
Heath KV; Hogg RS; Singer J; Chan KJ; O'Shaughnessy MV; Montaner JS
J Acquir Immune Defic Syndr; 2002 Aug; 30(4):440-7. PubMed ID: 12138351
[TBL] [Abstract][Full Text] [Related]
10. Self-reported signs of lipodystrophy by persons living with HIV infection.
Dreezen C; Schrooten W; de Mey I; Goebel FD; Dedes N; Florence E; Colebunders R;
Int J STD AIDS; 2002 Jun; 13(6):393-8. PubMed ID: 12015013
[TBL] [Abstract][Full Text] [Related]
11. New-onset diabetes in HIV-treated adults: predictors, long-term renal and cardiovascular outcomes.
Putcharoen O; Wattanachanya L; Sophonphan J; Siwamogsatham S; Sapsirisavat V; Gatechompol S; Phonphithak S; Kerr SJ; Chattranukulchai P; Avihingsanon Y; Ruxrungtham K; Avihingsanon A;
AIDS; 2017 Jul; 31(11):1535-1543. PubMed ID: 28398958
[TBL] [Abstract][Full Text] [Related]
12. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy.
Carr A; Miller J; Eisman JA; Cooper DA
AIDS; 2001 Apr; 15(6):703-9. PubMed ID: 11371684
[TBL] [Abstract][Full Text] [Related]
13. Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy.
Heath KV; Chan KJ; Singer J; O'Shaughnessy MV; Montaner JS; Hogg RS
Int J Epidemiol; 2002 Oct; 31(5):1016-20. PubMed ID: 12435777
[TBL] [Abstract][Full Text] [Related]
14. HIV lipodystrophy: a review.
Kravcik S
HIV Clin Trials; 2000; 1(3):37-50. PubMed ID: 11590504
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and risk factors of metabolic syndrome in Ethiopia: describing an emerging outbreak in HIV clinics of the sub-Saharan Africa - a cross-sectional study.
Abdela AA; Yifter H; Reja A; Shewaamare A; Ofotokun I; Degu WA
BMJ Open; 2023 Dec; 13(12):e069637. PubMed ID: 38070936
[TBL] [Abstract][Full Text] [Related]
16. Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome.
Barbaro G
Curr Pharm Des; 2007; 13(21):2208-13. PubMed ID: 17627554
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
van der Valk M; Gisolf EH; Reiss P; Wit FW; Japour A; Weverling GJ; Danner SA;
AIDS; 2001 May; 15(7):847-55. PubMed ID: 11399957
[TBL] [Abstract][Full Text] [Related]
18. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
19. Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study.
Cames C; Pascal L; Ba A; Mbodj H; Ouattara B; Diallo NF; Msellati P; Mbaye N; Sy Signate H; Blanche S; Diack A;
BMC Infect Dis; 2018 Aug; 18(1):374. PubMed ID: 30081838
[TBL] [Abstract][Full Text] [Related]
20. HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.
Martin A; Moore CL; Mallon PW; Hoy JF; Emery S; Belloso WH; Phanuphak P; Ferret S; Cooper DA; Boyd MA;
PLoS One; 2013; 8(10):e77138. PubMed ID: 24204757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
